Literature DB >> 6203817

Determination of low molecular weight heparin in clinical laboratory.

J van Putten, M van de Ruit, M Beunis, H C Hemker.   

Abstract

The applicability was investigated of automated spectrophotometric heparin assays and three clotting assays for determination of two low molecular weight (LMW) heparin fractions: Org 10172 and DxN10 and two infractionated commercially available heparins. The relative activity of the two commercially available heparins was similar in the anti-Xa assay, in the anti-IIa assay and in 3 clotting assays. The LMW heparins showed markedly different relative activity in all 5 assays. The activities of those heparin preparations relative to the standard heparin were compared in the 5 assays, but standardization against a standard heparin preparation appeared impossible. Methods of heparin determination can be used to monitor treatment with a heparin preparation only if the same preparation is used as a reference substance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203817     DOI: 10.1159/000215057

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  2 in total

1.  Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.

Authors:  Kakunoshin Yoshida; Hideo Wada; Masahiro Hasegawa; Hiroki Wakabayashi; Takeshi Matsumoto; Yuji Shimokariya; Katsura Noma; Norikazu Yamada; Atsumasa Uchida; Tsutomu Nobori; Akihiro Sudo
Journal:  Int J Hematol       Date:  2012-01-21       Impact factor: 2.490

2.  Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement.

Authors:  Kakunoshin Yoshida; Hideo Wada; Masahiro Hasegawa; Hiroki Wakabayashi; Honami Ando; Seika Oshima; Takeshi Matsumoto; Yuji Shimokariya; Katsura Noma; Norikazu Yamada; Atsumasa Uchida; Tsutomu Nobori; Akihiro Sudo
Journal:  Int J Hematol       Date:  2011-09-22       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.